Effect of Fuzheng Quxie Formula on immune function and disease⁃free survival in postoperative patients with stage ⅠA micropapillary/solid‑dominant positive invasive lung adenocarcinoma

MEI Na; WU Jianchun; LUO Yingbin; JIANG Lei; LI Yan

doi:10.16305/j.1007-1334.2024.z20240602005

您当前的位置：

首页 >

文章列表页 >

Effect of Fuzheng Quxie Formula on immune function and disease⁃free survival in postoperative patients with stage ⅠA micropapillary/solid‑dominant positive invasive lung adenocarcinoma

更新时间：2024-12-23

- Effect of Fuzheng Quxie Formula on immune function and disease⁃free survival in postoperative patients with stage ⅠA micropapillary/solid‑dominant positive invasive lung adenocarcinoma
- Shanghai Journal of Traditional Chinese Medicine Vol. 58, Issue 12, Pages: 125-129(2024)
- 作者机构：
  
  1.上海中医药大学附属市中医医院肿瘤科（上海 200071）
  2.上海市肺科医院胸外科（上海 200433）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2024.z20240602005
  CLC：
- Published：10 December 2024，
  
  Received：02 June 2024，
- 稿件说明：
移动端阅览
梅娜,吴建春,骆莹滨,等.扶正祛邪方对ⅠA期微乳头/实性成分阳性浸润性肺腺癌术后患者免疫功能及无病生存期的影响[J].上海中医药杂志,2024,58(12):125-129.

MEI Na,WU Jianchun,LUO Yingbin,et al.Effect of Fuzheng Quxie Formula on immune function and disease⁃free survival in postoperative patients with stage ⅠA micropapillary/solid‑dominant positive invasive lung adenocarcinoma[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(12):125-129.
梅娜,吴建春,骆莹滨,等.扶正祛邪方对ⅠA期微乳头/实性成分阳性浸润性肺腺癌术后患者免疫功能及无病生存期的影响[J].上海中医药杂志,2024,58(12):125-129. DOI： 10.16305/j.1007-1334.2024.z20240602005.

MEI Na,WU Jianchun,LUO Yingbin,et al.Effect of Fuzheng Quxie Formula on immune function and disease⁃free survival in postoperative patients with stage ⅠA micropapillary/solid‑dominant positive invasive lung adenocarcinoma[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(12):125-129. DOI： 10.16305/j.1007-1334.2024.z20240602005.

摘要

目的

观察扶正祛邪方对ⅠA期微乳头/实性成分阳性（MP/SD+）浸润性肺腺癌术后患者免疫功能及无病生存期（DFS）的影响，为ⅠA期肺腺癌患者的术后治疗提供参考。

方法

将216例ⅠA期MP/SD+浸润性肺腺癌术后患者分为治疗组（108例）、对照组（108例），对照组不予抗肿瘤干预，治疗组予扶正祛邪方口服，定期随访。观察两组外周血免疫指标［CD3

、CD4

、CD8

、自然杀伤（NK）细胞表达水平及CD4

/CD8

比值］的变化情况，记录DFS，计算无病生存率，绘制Kaplan-Meier生存曲线，并进行安全性评价。

结果

①最终纳入统计者213例，其中治疗组105例、对照组108例。②治疗前后组内比较，治疗组CD3

、NK细胞比例上升（

0.05），CD8

比例下降（

0.05）；对照组免疫指标变化差异无统计学意义（

0.05）。组间治疗后比较，治疗组CD3

、NK细胞比例及CD4

/CD8

比值高于对照组（

0.05），CD8

比例低于对照组（

0.05）。③治疗组105例患者中，5例患者复发，1年、2年和3年无病生存率分别为98.9%、96.5%和92.0%；对照组108例患者中，11例复发，1年、2年和3年无病生存率分别为94.9%、89.8%和81.9%。绘制Kaplan-Meier生存曲线后，两组差异有统计学意义（

0.05）。④试验期间，两组患者血常规、肝肾功能等安全性指标未见明显变化。

结论

扶正祛邪方可有效调节ⅠA期MP/SD+浸润性肺腺癌术后患者的免疫功能，进而延长DFS，改善预后。

Abstract

Objective

To observe the effects of Fuzheng Quxie Formula （FQF） on immune function and disease-free survival （DFS） in postoperative patients with stage ⅠA micropapillary/solid-dominant positive （MP/SD+） invasive lung adenocarcinoma， providing a reference for postoperative treatment in these patients.

Methods

A total of 216 postoperative patients with stage ⅠA MP/SD+ invasive lung adenocarcinoma were divided into a treatment group （

=108） and a control group （

=108）. The control group received no antitumor intervention， while the treatment group was administered FQF orally and followed up regularly. The variations in peripheral blood immune markers， including CD3

， CD4

， CD8

， natural killer （NK） cell expression levels， and the CD4

/CD8

ratio， were assessed in both groups. DFS was recorded， the disease-free survival rate was calculated， Kaplan-Meier survival curves were plotted， and safety was assessed.

Results

①A total of 213 patients were included in the final analysis， with 105 in the treatment group and 108 in the control group. ②Intra-group comparisons before and after treatment showed a significant increase in the proportions of CD3

and NK cells in the treatment group （

0.05）， along with a decrease in the CD8

proportion （

0.05）. In the control group， no statistically significant changes were observed in immune markers （

0.05）. After treatment， inter-group comparisons revealed that the treatment group had significantly higher CD3

， NK cell proportions， and higher CD4

/CD8

ratio than the control group （

0.05）， while the treatment group had lower CD8

proportion than the control group （

0.05）. ③Among the 105 patients in the treatment group， 5 experienced recurrence， with 1-year， 2-year， and 3-year disease-free survival rates of 98.9%， 96.5%， and 92.0%， respectively. Among the 108 patients in the control group， 11 experienced recurrence， with 1-year， 2-year， and 3-year disease-free survival rates of 94.9%， 89.8%， and 81.9%， respectively. Kaplan-Meier survival curves indicated statistically significant differences between the two groups （

0.05）. ④During the trial， no significant changes were observed in safety indicators including routine blood tests and liver and kidney function tests in both groups.

Conclusion

FQF can effectively regulate immune function in postoperative patients with stage ⅠA MP/SD+ invasive lung adenocarcinoma， thereby extending DFS and improving prognosis.

关键词

肺癌预后中医药疗法免疫功能无病生存期临床试验

Keywords

lung cancerprognosistraditional Chinese medicine therapyimmune functiondisease-free survivalclinical trial

references

BADE B C， CRUZ C S D. Lung cancer 2020： epidemiology， etiology， and prevention［J］. Clin Chest Med， 2020， 41（1）： 1-24.

王少明，郑荣寿，韩冰峰，等. 2022年中国人群恶性肿瘤发病与死亡年龄特征分析［J］. 中国肿瘤， 2024， 33（3）： 165-174.

XIA C F， DONG X S， LI H， et al.Cancer statistics in China and United States， 2022： profiles， trends， and determinants［J］. Chin Med J， 2022， 135（5）： 584-590.

WANG Y， YAN Q， FAN C， et al. Overview and countermeasures of cancer burden in China［J］.Sci China Life Sci， 2023， 66（11）： 2515-2526.

KUHN E， MORBINI P， CANCELLIERI A， et al. Adenocarcinoma classification： patterns and prognosis［J］. Pathologica， 2018， 110（1）： 5-11.

ZHANG Y， WANG R， CAI D， et al. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component［J］. J Thorac Oncol， 2014， 9（12）： 1772-1778.

UJIIE H， KADOTA K， CHAFT J E， et al. Solid predominant histologic subtype in resected stage Ⅰ lung adenocarcinoma is an independent predictor of early， extrathoracic，multisite recurrence and of poor postrecurrence survival［J］. J Clin Oncol， 2015， 33（26）： 2877-2884.

PENG B， LI G， GUO Y. Prognostic significance of micropapillary and solid patterns in stage ⅠA lung adenocarcinoma［J］. Am J Transl Res， 2021， 13（9）： 10562-10569.

LEE G， LEE H Y， JEONG J Y， et al. Clinical impact of minimal micropapillary pattern in invasive lung adenocarcinoma： prognostic significance and survival outcomes［J］. Am J Surg Pathol， 2015， 39（5）： 660-666.

JEON H W， KIM Y D， SIM S B， et al. Significant difference in recurrence according to the proportion of high grade patterns in stage ⅠA lung adenocarcinoma［J］. Thorac Cancer， 2021， 12（13）： 1952-1958.

GOLDSTRAW P， CHANSKY K， CROWLEY J， et al. The IASLC Lung Cancer Staging Project：Proposals for Revision of the TNM Stage Groupings in the Forthcoming（Eighth）Edition of the TNM Classification for Lung Cancer［J］. J Thorac Oncol， 2016， 11（1）： 39-51.

POSTMUS P E， KERR K M， OUDKERK M， et al. Early and locally advanced non-small-cell lung cancer（NSCLC）： ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up［J］. Ann Oncol， 2017， 28（suppl_4）： iv1-iv21.

KRIS M G， GASPAR L E， CHAFT J E， et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage Ⅰ to ⅢA Completely Resected Non-Small-Cell Lung Cancers：American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update［J］. J Clin Oncol， 2017， 35（25）： 2960-2974.

ZHANG S F， CHEN W Q， WANG Y L， et al. Chinese herbal prescription Fu-Zheng-Qu-Xie Prevents recurrence and metastasis of postoperative early-stage lung adenocarcinoma：a prospective cohort study followed with potential mechanism exploration［J］. Oxid Med Cell Longev， 2021， 2021： 6673828.

刘素彤，张素芳，骆莹滨，等. 扶正祛邪方提高肺癌患者无进展生存期回顾性队列研究［J］. 中医学报， 2019， 34（7）： 1497-1501.

方志红，李雁，李天苗. 扶正祛邪方联合化疗治疗晚期非小细胞肺癌疗效分析［J］. 时珍国医国药， 2013， 24（10）： 2433-2434.

徐静，朱为康，郭鹏，等. 扶正祛邪方联合靶向治疗晚期非小细胞肺癌疗效及对免疫功能的影响［J］. 现代中西医结合杂志， 2022， 31（11）： 1538-1541.

方志红，李雁，王艳春，等. 扶正祛邪方对肺癌A549细胞EMT的抑制作用及机制研究［J］. 中华中医药学刊， 2015， 33（3）： 536-538.

李赛凯，骆莹滨，吴建春，等. 益气扶正方对Lewis肺癌小鼠抑瘤作用的实验研究［J］. 中华中医药学刊， 2017， 35（3）： 569-572.

梅娜，吴建春，骆莹滨，等. 中药有效成分调控代谢重编程抗肿瘤研究进展［J］. 上海中医药杂志， 2023， 57（10）： 95-100.

DETTERBECK F C， BOFFA D J， KIM A W， et al. The Eighth Edition Lung Cancer Stage Classification［J］. Chest， 2017， 151（1）： 193-203.

TSUBOKAWA N， MIMAE T， MIYATA Y， et al. Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma［J］. Jpn J Clin Oncol， 2016， 46（11）： 1015-1021.

YOSHIZAWA A， MOTOI N， RIELY G J， et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma：prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases［J］. Mod Pathol， 2011， 24（5）： 653-664.

陈勇. ⅠA期浸润性肺腺癌的不同病理亚型的远期预后分析［D］. 大连：大连医科大学， 2022.

陈城，张斌杰. 伴实性或微乳头成分ⅠA期肺腺癌的预后分析［J］. 现代实用医学， 2021， 33（10）： 1276-1279.

ZHAO Z R， LAU R W H， LONG H， et al. Novel method for rapid identification of micropapillary or solid components in early-stage lung adenocarcinoma［J］. J Thorac Cardiovasc Surg， 2018， 156（6）： 2310-2318.

YUAN Y G， MA G， ZHANG Y Q， et al.Presence of micropapillary and solid patterns are associated with nodal upstaging and unfavorable prognosis among patient with cT1N0M0 lung adenocarcinoma：a large-scale analysis［J］. J Cancer Res Clin Oncol， 2018， 144（4）： 743-749.

YAGI Y， ALY R G， TABATA K， et al. Three-dimensional histologic， immunohistochemical， and multiplex immunofluorescence analyses of dynamic vessel co-option of spread through air spaces in lung adenocarcinoma［J］. J Thorac Oncol， 2020， 15（4）： 589-600.

YOSHIDA Y， NITADORI J I， SHINOZAKI-USHIKU A， et al. Micropapillary histological subtype in lung adenocarcinoma of 2 cm or less：impact on recurrence and clinical predictors［J］. Gen Thorac Cardiovasc Surg， 2017， 65（5）： 273-279.

SONG T， JIANG L， ZHOU Z， et al. Impacts of thoracoscopic surgery and high grade histologic subtypes on spread through air spaces in small stage Ⅰ lung adenocarcinomas［J］. J Cancer Res Clin Oncol， 2019， 145（9）： 2375-2382.

杨佳，李雁. 李雁教授从“阴阳平衡”辨治肺癌经验［J］. 时珍国医国药， 2014， 25（2）： 465-466.

WALDMAN A D， FRITZ J M，LENARDO M J. A guide to cancer immunotherapy： from T cell basic science to clinical practice［J］. Nat Rev Immunol， 2020， 20（11）： 651-668.

CHRAA D， NAIM A， OLIVE D， et al. T lymphocyte subsets in cancer immunity： Friends or foes［J］. J Leukoc Biol， 2019， 105（2）： 243-255.

TSAI H F， HSU P N. Cancer immunotherapy by targeting immune checkpoints：mechanism of T cell dysfunction in cancer immunity and new therapeutic targets［J］. J Biomed Sci， 2017， 24（1）： 35.

SUN L， SU Y， JIAO A， et al. T cells in health and disease［J］. Signal Transduct Target Ther， 2023， 8（1）： 235.

WANG Y Y， ZHOU N， LIU H S， et al. Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression［J］. Cancer Med， 2020， 9（14）： 5086-5094.

CENERENTI M， SAILLARD M， ROMERO P， et al. The Era of Cytotoxic CD4 T Cells［J］. Front Immunol， 2022， 13： 867189.

LUCKHEERAM R V， ZHOU R， VERMA A D， et al. CD4+ T cells： differentiation and functions［J］. Clin Dev Immunol， 2012， 2012： 925135.

OH D Y， FONG L. Cytotoxic CD4+ T cells in cancer： Expanding the immune effector toolbox［J］. Immunity， 2021， 54（12）： 2701-2711.

HUANG Y， JIA A， WANG Y， et al. CD8+ T cell exhaustion in anti‑tumour immunity： The new insights for cancer immunotherapy［J］. Immunology， 2023， 168（1）： 30-48.

PERA A， CAMPOS C， LÓPEZ N， et al. Immunosenescence：Implications for response to infection and vaccination in older people［J］. Maturitas， 2015， 82（1）： 50-55.

张楠，周晓燕，卞涛. 外周血T淋巴细胞亚群检测在非小细胞肺癌中的临床意义［J］. 当代医学， 2020， 26（22）： 80-82.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical research on effects of Fuzheng Quxie Formula on preventing recurrence and metastasis in stage ⅠB⁃ⅡB non⁃small cell lung cancer and on humoral immune function

Effect of Fuzheng Quxie Formula on progression⁃free survival in lung cancer patients

CiteSpace and VOSviewer⁃based analysis of current status and development trends in lung cancer metastasis research in China over past 20 years

Clinical efficacy of Yiqi Yangyin Jiedu Formula combined with tislelizumab in treatment of driver‑gene‑negative advanced NSCLC and its impact on peripheral immune indicators

Clinical observation of Zengye Jiedu Decoction in prevention and treatment of chemotherapy⁃induced oral mucositis in adult patients with Ph/BCR‑ABL1‑negative acute lymphoblastic leukemia

Related Author

XU Lili

LI Yan

ZHANG Sufang

LUO Yingbin

ZHANG Bo

ZHOU Yiyang

ZHANG Minfeng

XU Lili

Related Institution

Department of Integrated Traditional Chinese and Western Medicine， Shanghai Pulmonary Hospital

Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Center of Clinical Oncology， Shanghai Municipal Hospital of Traditional Chinese Medicine

Cancer Research Institute， Shanghai Municipal Hospital of Traditional Chinese Medicine

Department of Hematological Oncology， Shanghai Jing'an District Beizhan Hospital

⁰